Study of a hormone gel for high-risk membranous nephropathy
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney disease must have been confirmed by a biopsy or a positive blood test for anti-PLA2R antibodies.
- Your doctor must classify you as high risk for worsening kidney function.
- Your kidney function (eGFR) must be 40 or higher on a recent blood test.
- If you’ve been treated with immunosuppressants before and your disease came back, it must have been long enough since your last dose (3 months for steroids, 6 months for certain stronger drugs, 12 months for rituximab).
- You cannot have type 1 or type 2 diabetes.
- You cannot have a known allergy to pig (porcine) products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This trial tests an investigational drug called YK012 for people with a kidney disease called primary membranous nephropathy. The study aims to see if YK012 is safe and helpful for those whose condition is very high risk and has not improved with standard treatments.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.